MEC Plus – MyMedflix Member Portal

Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

MEC Plus

Speciality

Author / Speaker

Title

Type of Media

Events

Search Entries:

Clear

«
1
…
43
44
45
46
47
…
115
»

How I Treat Multiple Myeloma in 2023

How I Treat Multiple Myeloma in 2023

Vivek Patel, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Luis E. Raez, MD

Artificial Intelligence in Oncology Care

Artificial Intelligence in Oncology Care

Kristina Rua, MSN, RN, OCN, ONN-CG

Waldenstrom’s Macroglobulinemia

Waldenstrom’s Macroglobulinemia

Steven P. Treon, MD, PhD, ,FACP, FRCP

$How to Navigate Through Relapsed-Refractory Myeloma Patient$

How to Navigate Through Relapsed-Refractory Myeloma Patient

Jonathan Kaufman, MD

How to Choose the Best 1L in a Newly Diagnosed Multiple Myeloma Patient?

How to Choose the Best 1L in a Newly Diagnosed Multiple Myeloma Patient?

Saad Usmani, MD, MBA, FACP

Thrombophilia & Thrombosis in Cancer Patients: Novel Advances

Thrombophilia & Thrombosis in Cancer Patients: Novel Advances

Cindy Leissinger, MD

Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions

Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions

Rami Komrokji, MD

Redefining Treatment Algorithms in B-cell Lymphomas: A Focus on CAR-T Cell TherapyLymphoma

Redefining Treatment Algorithms in B-cell Lymphomas: A Focus on CAR-T Cell TherapyLymphoma

Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

De Novo Acute Myeloid Leukemia

De Novo Acute Myeloid Leukemia

Richard Stone, MD

Navigating Payor Barriers to Access of Oncology Pharmaceuticals: Real-World Case Approach

Navigating Payor Barriers to Access of Oncology Pharmaceuticals: Real-World Case Approach

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE

The Art-of-Medicine in Treating Chronic Lymphocytic Leukemia

The Art-of-Medicine in Treating Chronic Lymphocytic Leukemia

Javier Pinilla-Ibarz, MD

Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine

Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine

Nakhle Saba, MD

Novel Therapeutic Advances for DLBCL & Hodgkin’s Disease

Novel Therapeutic Advances for DLBCL & Hodgkin’s Disease

Eduardo Sotomayor, MD

T-Cell NHL: Novel Approaches & Challenges

T-Cell NHL: Novel Approaches & Challenges

Francine M. Foss, MD

ADC in NSCLC: CEACAM5 and Teliso-V

ADC in NSCLC: CEACAM5 and Teliso-V

Julia Rotow, MD

ADC in NSCLC: TROP2 and HER3 in NSCLC

ADC in NSCLC: TROP2 and HER3 in NSCLC

Hossein Borghaei, MD

EGFRex20ins, METex14 and RET in NSCLC

EGFRex20ins, METex14 and RET in NSCLC

Mark Socinski, MD

K-RAS and ERBB2 Mutation in NSCLC

K-RAS and ERBB2 Mutation in NSCLC

Yasir Elamin, MD

Neoadjuvant and Adjuvant Immunotherapy in Early Stage Lung Cancer

Neoadjuvant and Adjuvant Immunotherapy in Early Stage Lung Cancer

Karen Kelly, MD

Novel Treatment for Unresectable Stage III NSCLC

Novel Treatment for Unresectable Stage III NSCLC

Edgardo S. Santos Castillero, MD, FACP

Small Cell Lung Cancer: 1L and Beyond

Small Cell Lung Cancer: 1L and Beyond

Anne Chiang, MD

Identifying and Targeting Mechanisms of Resistance to 3rd Generation EGFR Inhibitors

Identifying and Targeting Mechanisms of Resistance to 3rd Generation EGFR Inhibitors

Ravi Salgia, MD

ALK: Choosing 1L & Mechanism of Resistance

ALK: Choosing 1L & Mechanism of Resistance

Ibiayi Dagogo-Jack, MD

Novel Advances in Mesothelioma

Novel Advances in Mesothelioma

Jorge E. Gomez, MD

Displaying 1,101 - 1,125 of 2,875

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok